Detalhe da pesquisa
1.
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Future Oncol
; 18(29): 3245-3254, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950603
2.
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
Invest New Drugs
; 39(6): 1633-1640, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34287772
3.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162804
4.
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 180(1): 60-70, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164606
5.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Blood
; 127(26): 3360-8, 2016 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27207788
6.
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Magn Reson Med
; 77(2): 814-825, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26918893
7.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26891420
8.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther
; 31(4): 517-526, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146006
9.
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 160(3): 321-30, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150919
10.
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332062
11.
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Exp Hematol
; 111: 79-86, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417741
12.
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Br J Haematol
; 155(5): 580-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21950583
13.
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Leuk Lymphoma
; 60(4): 894-903, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30277102
14.
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
J Hematol Oncol
; 11(1): 68, 2018 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29776373
15.
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
J Clin Pharmacol
; 58(1): 114-121, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28783865
16.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
J Clin Pharmacol
; 58(2): 180-192, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28800141
17.
Phase I study of the anti-α5ß1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(2): 339-351, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905898
18.
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
Clin Lymphoma Myeloma Leuk
; 17(7): 433-437, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576443
19.
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Exp Hematol
; 114: 54-60, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934183
20.
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
J Clin Pharmacol
; 56(10): 1288-95, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26872892